Clinical effects of combined zero-ischemia microwave ablation during laparoscopic partial nephrectomy for stage Ⅰ renal cancer
ZHENG Huijie
TAN Gongxiang
CHEN Yamei
YU Chunyan
XU Wenfang
DU Shengting
GAO Shiliang
YU Zhu
LIU Ming
YU Mingzhu
Abstract：Methods A retrospective analysis was performed on the clinical data of 95 patients with clinically stagedⅠ(pT1)renal cell carcinoma admitted to the Department of Urology,the 908th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army,from October 2020 to January 2022.According to the surgical method,patients were divided into two groups:47 patients who received traditional LPN(with renal artery clamping)were assigned to the control group,and 48 patients who underwent LPN combined with zero-ischemia microwave ablation for renal cell carcinoma were assigned to the study group.The SPSS 25.0 statistical system was used to analyze and compare perioperative conditions,renal function indicators before and after surgery,inflammatory-stress factors,quality of life,functional status,and renal re-gion pain intensity between the two groups.The incidence of postoperative complications and recurrence rate were also com-pared between the two groups.Results Independent samples t-test showed that the operation time of the study group[(64.28±11.79)minutes]was longer than that of the control group[(57.61±10.83)minutes],while the postoperative drain-age time[(5.19±1.06)days]and hospital stay[(11.28±2.47)days]were shorter than those of the control group[(6.54±1.37)days and(14.35±3.12)days,respectively],with statistically significant differences(all P<0.05).On the 3rd day after surgery,the levels of C-reactive protein(CRP),tumor necrosis factor-α(TNF-α),malondialdehyde(MDA),and epineph-rine(E)in the study group were(12.67±2.18)mg/L,(24.59±7.43)ng/L,(2.56±0.49)μmol/L,and(40.79±7.05)μg/L,respectively,which were lower than those in the control group[(15.30±2.79)mg/L,(30.42±8.16)ng/L,(3.12±0.57)μmol/L,and(48.21±7.84)μg/L,respectively],with statistically significant differences(all P<0.05).At 3 months after surgery,the levels of serum creatinine(Cr)and blood urea nitrogen(BUN)in the study group were(95.13±17.65)μmol/L and(4.12±1.10)mmol/L,respectively,lower than those in the control group[(112.39±20.18)μmol/L and(7.36±1.59)mmol/L,respectively];the estimated glomerular filtration rate(eGFR)and creatinine clearance rate(Ccr)in the study group were(76.18±5.63)mL/min and(68.54±9.31)mL/min,respectively,higher than those in the control group[(71.49±5.21)mL/min and(57.26±8.85)mL/min,respectively],with statistically significant differences(all P<0.05).At 3 months after sur-gery,the scores of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30(EORTC QLQ-C30)and Karnofsky Performance Status(KPS)in the study group were(78.53±7.11)and(86.19±4.38),respectively,higher than those in the control group[(73.46±7.68)and(82.45±5.17),respectively];the Visual Analogue Scale(VAS)score for pain in the study group[(0.95±0.31)]was lower than that in the control group[(1.46±0.43)],with statistically significant differences(all P<0.05).Chi-square test showed that the total incidence of complications in the study group was 4.17%,which was lower than 19.15%in the control group,with a statistically significant difference(P<0.05).There was no statistically significant difference in the 1-year postoperative recurrence rate between the two groups(P>0.05).Conclusion LPN combined with zero-ischemia microwave ablation for Stage Ⅰ renal cell carcinoma can achieve zero isch-emia,reduce the body's inflammatory-stress response,decrease postoperative complications,have less impact on renal func-tion,and help alleviate renal region pain,improve the body's functional status and quality of life.Objective To explore the clinical efficacy of laparoscopic partial nephrectomy(LPN)combined with zero-ischemia microwave ablation for Stage Ⅰ re-nal cell carcinoma,and its effects on renal function,complications,and quality of life.
Keywords：microwave ablationlaparoscopic partial nephrectomyrenal cell carcinomainflammationquality of lifecomplications
Publication Date：2025-10-28
Online Publishing Date：2026-01-15(First online date of this platform, not the publication date of the document)
Pages：8( 303-310 )